iTeos Therapeutics Stock Quote ITOS - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

16.505

Bid

16.12

Ask

17.29

Volume

305,463

15.72 Day's Range 16.52

8.20 52 Week Range 18.75

Market Cap

568.214M

Previous Close

15.73

Open

16.33

Last Trade

17.29

Last Trade Time

Financial Volume

$ 4,918,870

VWAP

16.103

Average Volume (3m)

462,657

Shares Outstanding

36,122,922

Dividend Yield

PE Ratio

-5.23

Earnings Per Share (EPS)

-3.12

Revenue

12.6M

Net Profit

-112.64M

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.iteostherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was $15.73. Over the last year, iTeos Therapeutics shares have traded in a share price range of $ 8.20 to $ 18.75.

iTeos Therapeutics currently has 36,122,922 shares outstanding. The market capitalization of iTeos Therapeutics is $568.21 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -5.23.

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.205	1.25766871166	16.3	17.71	15.56	295276	16.75017805	CS
4	1.655	11.1447811448	14.85	17.71	13.06	334570	15.41039106	CS
12	5.675	52.4007386888	10.83	18.75	10.6039	462657	16.12444198	CS
26	5.845	54.8311444653	10.66	18.75	9.7	359093	14.07883051	CS
52	1.925	13.2030178326	14.58	18.75	8.2	399059	12.43798194	CS
156	-8.615	-34.2953821656	25.12	52.43	8.2	359777	20.6530796	CS
260	-3.195	-16.2182741117	19.7	52.43	8.2	340128	22.1341974	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.14M
CMAXCareMax Inc	$ 5.19 (228.48%)	102.64M
NUKKNukkleus Inc	$ 0.499 (55.94%)	26.2M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.88M
ONDSOndas Holdings Inc	$ 1.1297 (34.06%)	2.19M
CGBSCrown LNG Holdings Ltd	$ 0.9902 (-29.77%)	3.29M
LGCBLinkage Global Inc	$ 3.7833 (-27.45%)	166.7k
SPECSpectaire Holdings Inc	$ 0.395 (-24.76%)	1.78M
GSUNGolden Sun Health Technology Group Ltd	$ 5.07 (-24.55%)	155.37k
SLNASelina Hospitality PLC	$ 0.0364 (-23.04%)	75.77M
NVDANVIDIA Corporation	$ 123.45 (4.68%)	221.22M
SQQQProShares UltraPro Short QQQ	$ 8.08 (-4.49%)	176.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
SERVServe Robotics Inc	$ 8.7192 (15.49%)	148.59M
NCPLNetcapital Inc	$ 0.1105 (6.25%)	121.97M